AHR Regulates Metabolic Reprogramming to Promote SIRT1-Dependent Keratinocyte Differentiation.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
04 2019
Historique:
received: 04 10 2017
revised: 17 09 2018
accepted: 01 10 2018
pubmed: 6 11 2018
medline: 3 4 2020
entrez: 6 11 2018
Statut: ppublish

Résumé

Activation of the transcription factor, AHR, in normal human epidermal keratinocytes increased AHR binding in the gene regions of the glucose transporter, SLC2A1, and the glycolytic enzyme, ENO1. This increased chromatin binding corresponded with AHR-dependent decreases in levels of SLC2A1 and ENO1 mRNA, protein, and activities. Studies of the ENO1 promoter showed activation of the AHR decreases the transcription of ENO1. Glycolysis was lowered by activation of the AHR as measured by decreases in glucose uptake and the production of pyruvate and lactate. Levels of ATP were also decreased. Downregulation of glucose metabolism, either by activation of the AHR, inhibition of glycolysis, inhibition of glucose transport, or inhibition of enolase, increased SIRT1 protein levels in normal human epidermal keratinocytes and the immortalized keratinocyte cell line, N/TERT-1. This increase in SIRT1 was abrogated by the addition of exogenous pyruvate. Moreover, keratinocyte differentiation in response to downregulation of glycolysis, either by activation of the AHR, inhibition of glucose transport, or inhibition of enolase, was dependent on SIRT1. These results indicate that regulation of glycolysis controls keratinocyte differentiation, and that activation of the AHR, by lowering the expression of SLC2A1 and ENO1, can determine this fate.

Identifiants

pubmed: 30393078
pii: S0022-202X(18)32714-3
doi: 10.1016/j.jid.2018.10.019
pmc: PMC6431567
mid: NIHMS1518086
pii:
doi:

Substances chimiques

AHR protein, human 0
Basic Helix-Loop-Helix Transcription Factors 0
Biomarkers, Tumor 0
DNA-Binding Proteins 0
Glucose Transporter Type 1 0
Receptors, Aryl Hydrocarbon 0
SLC2A1 protein, human 0
Tumor Suppressor Proteins 0
RNA 63231-63-0
SIRT1 protein, human EC 3.5.1.-
Sirtuin 1 EC 3.5.1.-
ENO1 protein, human EC 4.2.1.11
Phosphopyruvate Hydratase EC 4.2.1.11
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

818-826

Subventions

Organisme : NIEHS NIH HHS
ID : R01 ES017014
Pays : United States

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Cell. 1976 Dec;9(4 Pt 1):511-21
pubmed: 1009573
Mol Endocrinol. 1999 Sep;13(9):1511-21
pubmed: 10478842
Mol Cell Biol. 2000 Feb;20(4):1436-47
pubmed: 10648628
Toxicol Appl Pharmacol. 2001 Sep 1;175(2):121-9
pubmed: 11543644
J Biol Chem. 1957 Feb;224(2):963-9
pubmed: 13405925
J Biochem Mol Biol. 2004 Mar 31;37(2):239-45
pubmed: 15469702
Nat Rev Mol Cell Biol. 2005 Apr;6(4):328-40
pubmed: 15803139
Cell Cycle. 2006 Jun;5(12):1258-61
pubmed: 16760649
FEBS Lett. 2008 Jul 9;582(16):2417-23
pubmed: 18544345
J Invest Dermatol. 2009 Jan;129(1):41-9
pubmed: 18563176
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4266-71
pubmed: 19255421
Toxicol Sci. 2011 Nov;124(1):128-37
pubmed: 21835898
Cell. 2011 Oct 28;147(3):629-40
pubmed: 21999944
Toxicol Sci. 2013 Mar;132(1):235-49
pubmed: 23152189
J Clin Invest. 2013 Feb;123(2):917-27
pubmed: 23348739
Sci Signal. 2013 Feb 05;6(261):ra8
pubmed: 23386745
J Pharmacol Exp Ther. 2013 Jun;345(3):419-29
pubmed: 23512538
Nat Commun. 2014 Aug 20;5:4738
pubmed: 25141024
J Allergy Clin Immunol. 2015 Apr;135(4):936-45.e4
pubmed: 25445829
J Invest Dermatol. 2015 May;135(5):1320-1328
pubmed: 25602157
J Invest Dermatol. 1966 Aug;47(1):35-8
pubmed: 25622347
J Invest Dermatol. 1966 May;46(5):473-6
pubmed: 25622360
J Invest Dermatol. 2016 Nov;136(11):2260-2269
pubmed: 27430407
ChemMedChem. 2016 Oct 19;11(20):2261-2271
pubmed: 27552707
Folia Neuropathol. 2016;54(3):212-233
pubmed: 27764514
J Invest Dermatol. 2017 Jun;137(6):1267-1276
pubmed: 28108301
Genes Dev. 2017 Feb 15;31(4):336-346
pubmed: 28314766
Front Immunol. 2017 Jul 21;8:837
pubmed: 28785263
J Invest Dermatol. 1966 Oct;47(4):293-5
pubmed: 4959305
Dev Biol. 1980 Feb;74(2):275-85
pubmed: 7371976
J Biol Chem. 1996 Dec 20;271(51):32529-37
pubmed: 8955077

Auteurs

Carrie Hayes Sutter (CH)

Department of Biological Sciences, University of Memphis, Memphis, Tennessee, USA; W. Harry Feinstone Center for Genomic Research, University of Memphis, Memphis, Tennessee, USA.

Kristin M Olesen (KM)

Department of Biological Sciences, University of Memphis, Memphis, Tennessee, USA.

Jyoti Bhuju (J)

Department of Biological Sciences, University of Memphis, Memphis, Tennessee, USA.

Zibiao Guo (Z)

W. Harry Feinstone Center for Genomic Research, University of Memphis, Memphis, Tennessee, USA.

Thomas R Sutter (TR)

Department of Biological Sciences, University of Memphis, Memphis, Tennessee, USA; W. Harry Feinstone Center for Genomic Research, University of Memphis, Memphis, Tennessee, USA. Electronic address: tsutter@memphis.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH